Obsidian Therapeutics

OverviewSuggest Edit

Obsidian Therapeutics aspires to extend adoptive immunotherapy to every patient with cancer. The Company creates adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs.

TypePrivate
Founded2015
HQCambridge, US
Websiteobsidiantx.com

Latest Updates

Employees (est.) (Oct 2020)55(-1%)
Cybersecurity ratingAMore

Key People/Management at Obsidian Therapeutics

Michael Gilman

Michael Gilman

Director
Erin Boyer

Erin Boyer

Vice President, Human Resources
David Aubuchon

David Aubuchon

Vice President, Finance
Karen Brown

Karen Brown

Senior Vice President, Intellectual Property and Legal Affairs
Ryan Daws

Ryan Daws

Chief Financial Officer
Kirsten Kester

Kirsten Kester

Vice President, Business Development
Show more

Obsidian Therapeutics Office Locations

Obsidian Therapeutics has an office in Cambridge
Cambridge, US (HQ)
1030 Massachusetts Ave #400
Show all (1)

Obsidian Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2015

Obsidian Therapeutics total Funding

$49.5 m

Obsidian Therapeutics latest funding size

$49.50 m

Time since last funding

3 years ago

Obsidian Therapeutics investors

Obsidian Therapeutics's latest funding round in December 2017 was reported to be $49.5 m. In total, Obsidian Therapeutics has raised $49.5 m
Show all financial metrics

Obsidian Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Obsidian Therapeutics Online and Social Media Presence

Embed Graph

Obsidian Therapeutics News and Updates

Obsidian Therapeutics Announces Bristol Myers Squibb Opt-In of cytoDRiVE™ Cell Therapy Candidate

CAMBRIDGE, Mass., Sept. 15, 2020 /PRNewswire/ -- Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable cell and gene therapies, today announced that Bristol Myers Squibb (NYSE:BMY) has exercised its option to an exclusive worldwide license to a cell therapy...

Obsidian Therapeutics Appoints Erin Boyer as Vice President, Human Resources

CAMBRIDGE, Mass., Sept. 24, 2019 /PRNewswire/ -- Obsidian Therapeutics, a biotechnology company pioneering controllable cell and gene therapies, today announced the appointment of Erin Boyer as Vice President, Human Resources. In her role, Ms. Boyer will be responsible for all aspects of...

Applied BioMath, LLC Announces Collaboration with Obsidian Therapeutics for Semi-Mechanistic Quantitative Modeling of a Novel Therapeutic Platform

CONCORD, Mass., Nov. 19, 2018 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced a collaboration with Obsidian Therapeutics to provide semi-mechanistic models and analysis...

Obsidian Therapeutics Blogs

Obsidian Therapeutics Frequently Asked Questions

  • When was Obsidian Therapeutics founded?

    Obsidian Therapeutics was founded in 2015.

  • Who are Obsidian Therapeutics key executives?

    Obsidian Therapeutics's key executives are Michael Gilman, Erin Boyer and David Aubuchon.

  • How many employees does Obsidian Therapeutics have?

    Obsidian Therapeutics has 55 employees.

  • Who are Obsidian Therapeutics competitors?

    Competitors of Obsidian Therapeutics include Z Factor, Mymetics and Elite Pharmaceuticals.

  • Where is Obsidian Therapeutics headquarters?

    Obsidian Therapeutics headquarters is located at 1030 Massachusetts Ave #400, Cambridge.

  • Where are Obsidian Therapeutics offices?

    Obsidian Therapeutics has an office in Cambridge.

  • How many offices does Obsidian Therapeutics have?

    Obsidian Therapeutics has 1 office.